|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
Regulus Therapeutics Inc, a biopharmaceutical company has just released the company's third quarter financials. The company CEO, Kleanthis G Xanthopoulos has stated one of the company's key focus is the execution of research and development plans and in particular the microRNA therapeutic programmes which will enable Regulus to file at least two INDs by 2014.
There is an increasing realisation that MiRNAs regulate cell metabolic processes which can also help in the fight against cancer growth. Advanced studies of microRNAs have revealed their manifold biological functions including the control of cell proliferation, cell cycle and cell death. MicroRNAs role in regulating metabolism has become a key focus for research programmes over recent yearsw which is driving growth in the microRNAs research tool market.
It is the MiRNAs role in perhaps controlling cancer growth is key to the interest in this field. Cancer cells display increased metabolic autonomy in comparison to non-transformed cells and MiRNAs regulate cell metabolic processes through complicated mehanisms, including directly targeting key tumor suppressors as well as multiple oncogenic signalling pathways.
MiRNAs like miR-375, miR-143, miR-14 and miR-29b participate in controlling cancer cell metabolism by regulating the expression of genes whose protein products either directly regulate metabolic machinery or indirectly modulate the expression of metabolic enzymes, serving as master regulators, which will hopefully lead to a new therapeutic strategy for malignant cancer.
The global MicroRNA research tools market is being driven by the drive to fund research into MicroRNA based therapeutics cancer programmes, with the industry forecast to be worth US$736 million by 2017.
In 2011, the MicroRNA research tools market was only worth US$295.3 million and in 2012 this industry is expected to see continued growth and be valued at US$338 million by the end of the year. Between the period 2012 to 2017, the MicroRNA research tools market is forecast to expand by a CAGR of 17.7%.
The MicroRNA research tools market can be segmented into several smaller sectors. The tools and reagents sector represents the largest, forecast to record a value of US$640 million by 2017. The MicroRNA therapeutics sector is estimated to be valued at US$120 million by 2017 expanding from a market base of US$60 million in 2012.
For more information on the MicroRNA research tools market, see the latest research: MicroRNA research tools market
Follow us on Twitter @CandMResearch
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.
Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.
We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.